We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
AstraZeneca is spending $68 million to acquire LogicBio Therapeutics, a move that brings two innovative gene editing platforms to the pharma giant’s fold. Read More
Roche is acquiring Good Therapeutics for $250 million in upfront cash, gaining Good’s conditionally active biologics (CAB) to create new immunotherapies for treating cancer. Read More